Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03723265 · ClinicalTrials.gov registry record

Personalized CRT - PSR

A clinical trial of Heart Failure, sponsored by Medtronic.

Completed
Registry status
1,517
Enrollment target
20
Study locations

NCT03723265: Completed study of Heart Failure, sponsored by Medtronic.

NCT03723265 is a study of Heart Failure that has completed, run by Medtronic. The registered enrollment target is 1,517 participants, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03723265, a study of Heart Failure, has completed, sponsored by Medtronic.

COMPLETED
Registry status
1,517 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the cardiac resynchronization therapy (CRT) response in a real-world patient population and evaluate options to address non-response and patient management.

Primary Outcome

A Clinical Composite Score (CCS) endpoint will be used to assess a change in CRT response for all patients from baseline to follow-up visits.

Conditions Studied

Interventions

  • DEVICE Cardiac Resynchronization Therapy

Study Locations (20)

California

  • - Bakersfield
  • - Chula Vista
  • - Palm Springs
  • - Rancho Mirage
  • - Redwood City
  • - Salinas
  • - San Diego
  • - Stanford
  • - Torrance
  • - Van Nuys

Arkansas

  • - Jonesboro
  • - Little Rock

Colorado

  • - Denver
  • - Lakewood

Alabama

  • - Birmingham

Alaska

  • - Anchorage

Arizona

  • - Gilbert

Connecticut

  • - New Haven

District of Columbia

  • - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,517 participants
Start Date 2012-01
Est. Completion 2022-04-28
Medtronic

30 total trials

What the finished NCT03723265 record still lists

NCT03723265 is an observational study that tracks outcomes without assigning an intervention. Its 1,517 participants enrollment target places it among the larger protocols in the corpus, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Cardiac Resynchronization Therapy is the first listed.

NCT03723265 names 20 study sites across 9 states, led by California, Arkansas, Colorado.

Frequently Asked Questions

What is clinical trial NCT03723265 about?

NCT03723265 is a clinical study titled "Personalized CRT - PSR". The purpose of this study is to evaluate the cardiac resynchronization therapy (CRT) response in a real-world patient population and evaluate options to address non-response and patient management.

What is the current status of trial NCT03723265?

This trial is currently completed. The enrollment target is 1,517 participants. The study started on 2012-01. Estimated completion is 2022-04-28.

What conditions does trial NCT03723265 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT03723265?

The interventions under investigation include: Cardiac Resynchronization Therapy (DEVICE).

Who is sponsoring clinical trial NCT03723265?

This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03723265 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03723265's enrollment target sits among peer trials

1,517 53rd of 397 higher than 345 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07232017 · 1,520 participants

    Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic

  • NCT05633654 · 1,514 participants · Phase 3

    Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  • NCT07136623 · 1,513 participants

    Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

  • NCT06876714 · 1,524 participants · Phase 3

    ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03723265, the US trial registry maintained by the National Library of Medicine. NCT03723265 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.